Pfizer's company logo. (Photo/CFP) |
China's
drug watchdog has decided to stop importing an injection from Pfizer, as the US
pharmaceutical maker failed in a supplementary application for drug exports.
China will
not import Pfizer's Fluconazole injection, used to treat monilial infection,
until the company makes correction, the State Food and Drug Administration
announced on Tuesday.
The
administration said it recently inspected Pfizer's Amboise factory in France
and found that the factory did not submitted relevant supplementary
applications in accordance with Chinese law and regulations.
The
administration had invited staff from the company for a meeting, it said.
It urged
overseas pharmaceutical companies to strictly abide by relevant Chinese laws
and regulations on drugs and warned them not to adopt "differentiated
treatment" policies in technological standards and drug quality.
Those who
violate Chinese laws and regulations will be warned or banned from exporting
drugs to or selling drugs in the country, according to the administration.
Regarding
the import ban, Pfizer said in a statement on Tuesday that the problem does not
involve safety and quality. Pfizer respects and values China's laws and
regulations and has taken correction measures, it said, adding that it will
continue to cooperate with the country's drug authorities to ensure all its
overseas factories supplying the Chinese market meet the legal requirements.
No comments:
Post a Comment